BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19789392)

  • 1. Contemporary imaging in sarcoma.
    Landa J; Schwartz LH
    Oncologist; 2009 Oct; 14(10):1021-38. PubMed ID: 19789392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
    Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
    Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
    Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
    Tewfik JN; Greene GS
    Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
    Peterson JJ
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 8. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative imaging for metastasectomy.
    Klippenstein DL; Lamonica DM
    Surg Oncol Clin N Am; 2007 Jul; 16(3):471-92, vii. PubMed ID: 17606189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of plain radiography, computed tomography, and magnetic resonance imaging in sarcoma evaluation.
    Massengill AD; Seeger LL; Eckardt JJ
    Hematol Oncol Clin North Am; 1995 Jun; 9(3):571-604. PubMed ID: 7649943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, investigations and staging of soft-tissue sarcoma.
    Rock MG
    Can J Surg; 1988 Nov; 31(6):385-9. PubMed ID: 3179847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance/positron emission tomography (MR/PET) oncologic applications: bone and soft tissue sarcoma.
    Partovi S; Chalian M; Fergus N; Kosmas C; Zipp L; Mansoori B; Ros PR; Robbin MR
    Semin Roentgenol; 2014 Oct; 49(4):345-52. PubMed ID: 25498231
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
    el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Musculoskeletal Sarcoma: Update on Imaging of the Post-treatment Patient.
    Garner HW; Kransdorf MJ
    Can Assoc Radiol J; 2016 Feb; 67(1):12-20. PubMed ID: 25660298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
    Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
    Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoma.
    Ceyssens S; Stroobants S
    Methods Mol Biol; 2011; 727():191-203. PubMed ID: 21331935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.